Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Goldin

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
Annals of the Rheumatic Diseases|December 3, 2014
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosisDonald P Tashkin, Elizabeth R Volkmann, Chi-Hong Tseng, et al.
Respiratory Research|February 28, 2025
Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registryAparna C Swaminathan, Jeremy M Weber, Jamie L Todd, et al.
Clinical and Experimental Rheumatology|June 26, 2010
Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trialsDinesh Khanna, Kevin K Brown, Philip J Clements, et al.
The Lancet. Rheumatology|September 25, 2023
Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trialsElizabeth R Volkmann, Donald P Tashkin, Richard Silver, et al.
American Journal of Respiratory and Critical Care Medicine|November 4, 2017
Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)Suzanne Kafaja, Philip J Clements, Holly Wilhalme, et al.
Arthritis Research & Therapy|December 26, 2015
Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trialsDinesh Khanna, Vivek Nagaraja, Chi-Hong Tseng, et al.
Thorax|April 10, 2025
Impact of quantitative radiological features of interstitial lung disease on immunomodulatory treatment response in three autoimmune interstitial lung disease cohortsScott M Matson, Grace Hyun J Kim, Stephen M Humphries, et al.
Arthritis and Rheumatism|May 28, 2011
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo GroupDinesh Khanna, Chi-Hong Tseng, Niloofar Farmani, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 5, 2017
Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and IIElizabeth R Volkmann, Donald P Tashkin, Ning Li, et al.
Chest|November 7, 2009
Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung studyJonathan Goldin, Robert Elashoff, Hyun J Kim, et al.
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
Annals of the Rheumatic Diseases|December 3, 2014
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosisDonald P Tashkin, Elizabeth R Volkmann, Chi-Hong Tseng, et al.
Respiratory Research|February 28, 2025
Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registryAparna C Swaminathan, Jeremy M Weber, Jamie L Todd, et al.
Clinical and Experimental Rheumatology|June 26, 2010
Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trialsDinesh Khanna, Kevin K Brown, Philip J Clements, et al.
The Lancet. Rheumatology|September 25, 2023
Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trialsElizabeth R Volkmann, Donald P Tashkin, Richard Silver, et al.
American Journal of Respiratory and Critical Care Medicine|November 4, 2017
Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)Suzanne Kafaja, Philip J Clements, Holly Wilhalme, et al.
Arthritis Research & Therapy|December 26, 2015
Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trialsDinesh Khanna, Vivek Nagaraja, Chi-Hong Tseng, et al.
Thorax|April 10, 2025
Impact of quantitative radiological features of interstitial lung disease on immunomodulatory treatment response in three autoimmune interstitial lung disease cohortsScott M Matson, Grace Hyun J Kim, Stephen M Humphries, et al.
Arthritis and Rheumatism|May 28, 2011
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo GroupDinesh Khanna, Chi-Hong Tseng, Niloofar Farmani, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 5, 2017
Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and IIElizabeth R Volkmann, Donald P Tashkin, Ning Li, et al.
Chest|November 7, 2009
Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung studyJonathan Goldin, Robert Elashoff, Hyun J Kim, et al.
Pageof 11